From the Corporate Update:
"The Directors have reviewed a number of diverse investment opportunities during the half year, that included but were not limited to the life sciences sector".
"Given the opportunities currently under review the Board is confident that a transaction is likely to occur in the near term".
Perhaps we could see some action before the end of this FY?
Ann: Appendix 4D and Half Year Report, page-2
Add ACL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.53 |
Change
0.055(1.59%) |
Mkt cap ! $708.4M | |||
| Open | High | Low | Value | Volume |
| $3.44 | $3.53 | $3.44 | $482.2K | 137.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 14169 | $3.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.53 | 2547 | 21 |
View Market Depth
| Last trade - 14.19pm 22/11/2024 (20 minute delay) ? |
| ACL (ASX) Chart |
